20/20 HealthCare Partners
VC Fund
Auburndale, United States
20/20 HealthCare Partners is a VC fund in Auburndale focused on Health Care and Biotechnology. 20/20 HealthCare Partners LLC is a Global Investment Group that invests primarily at the earliest stage of technology & life science innovation. We have a long history of creating value by partnering with entrepreneurs, executives and strategic partners in the healtcare community. Through strategic advice, team building, productdevelopment and syndicated investment, we are committed to helping our partners build valuable companies that impact healthcare and improve quality of life.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries 20/20 HealthCare Partners invests in
Stages 20/20 HealthCare Partners invests in
Countries 20/20 HealthCare Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hillel Bachrach
|
|||
Jonathan J. Fleming
|
|||
|
Len Singer
|
|||
Ronny Vinasco Bachrach
|
Investment Focus
Industry
- Health Care 4 (31%)
- Biotechnology 4 (31%)
- Therapeutics 3 (23%)
- Software 2 (15%)
- Life Science 2 (15%)
Stage
- Funding Round 6 (46%)
- Series A 3 (23%)
- Venture - Series Unknown 2 (15%)
- Series C 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christine Bunt
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Hillel Bachrach
Managing Partner
|
Managing Partner | Total investments: 2 | Find email | |
|
Jonathan J. Fleming
Advisory Board
|
Advisory Board | Total investments: 9 | Find email | |
|
Len Singer
Financial & Structuring Advisor
|
Financial & Structuring Advisor | Total investments: 0 | Find email | |
|
Ronny Vinasco Bachrach
Marketing Director
|
Marketing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Variantyx
|
Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing. | Venture - Series Unknown / Oct 18, 2023 | |
|
Variantyx
|
Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing. | $41.5M / Series C / Feb 12, 2022 | |
|
Variantyx
|
Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing. | $20M / Series C / Mar 15, 2021 | |
Coagulo Medical Technologies
|
Coagulo is transforming medicine with the first portable and connected precision-medicine platform for smarter management of coagulation, enabling better healthcare outcomes for everyone. | $6.5M / Dec 22, 2020 | |
XRHealth
|
XRHealth is a medical device company that develops XR (VR\AR) therapeutic platform. The XRHealth Platform combines medical applications with advanced data analytics and remote monitoring, providing a comprehensive solution for clinicians and patients and pharma companies. The XRHealth Platform collects and analyzes patient interactions withvirtual objects in virtual environments. AI cloud computing algorithms let us deliver an enhanced experience and real-time data analytics that can be used in clinics and in the home. With our technology, patients can analyze and quantify their own performance and track their own improvement over time.XRHealth is the first Certified Virtual Reality (VR) Medical Company to develop FDA/CE Registered Medical Applications. Our products focus on motor, cognitive, physical, psychological, postural ability and pain assessment and treatment. | $7M / Venture - Series Unknown / Apr 22, 2020 | |
EnClear Therapies
|
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | $10M / Series A / Feb 19, 2020 | |
Verseau Therapeutics
|
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients fromimmunotherapy. | $50M / Oct 21, 2019 | |
SQZ Biotech
|
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $5M / Series A / Jun 24, 2015 | |
EightSpokes, Inc.
|
EightSpokes is an intelligent cloud-based solution for programme and portfolio management in the life sciences. It also provides a solution for launch and programme management, lifecycle management, mergers and acquisitions, collaborative planning, and synchronised execution. | Jan 01, 2015 | |
Physiq
|
physIQ has developed a personalized physiology analytic platform (PPA) for use in both the regulated healthcare market as well as the unregulated health and fitness market. The technology is designed to detect subtle changes in vital signs and other health indicators to help clinicians manage patients with chronic illness, and to help consumerstrack their own health and fitness levels. The key differentiator between the physIQ platform and other technologies is that it constructs a personalized baseline norm for each person monitored, rather than simple trending or comparison to population-based statistics. Our technology can also be embedded into patient monitoring devices from other manufacturers who are seeking to design "smarter" products. | $3.7M / Nov 04, 2013 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does 20/20 HealthCare Partners invest in?
20/20 HealthCare Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Funding Round and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact 20/20 HealthCare Partners?
Public channels for 20/20 HealthCare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 20/20 HealthCare Partners?
The team at 20/20 HealthCare Partners includes Christine Bunt (Venture Partner), Hillel Bachrach (Managing Partner) and Jonathan J. Fleming (Advisory Board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
